Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Data on gene therapy described by researchers at University of California
March 11th, 2008
Investigators publish new data in the report 'Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen.' "Heteroclitic peptides are used to enhance the immunogenicity of tumor-associated Ags to break T cell tolerance to these self-proteins. One such altered peptide ligand (Cap1-6D) has been derived from an epitope in human carcinoembryonic Ag, CEA(605-613) (Cap1)," scientists in the United States report. "Clinical responses have been seen in colon cancer patients receiving a tumor vaccine comprised of this altered peptide. Whether Cap1-6D serves as a T cell agonist for Cap1-specific T cells or induces different T...
Source: Cancer Weekly (2008-03-11)
|
